JAGX vs. FBIO, VYNE, EYEN, DRRX, UNCY, LEXX, CARA, NRXP, CASI, and HCWB
Should you be buying Jaguar Health stock or one of its competitors? The main competitors of Jaguar Health include Fortress Biotech (FBIO), VYNE Therapeutics (VYNE), Eyenovia (EYEN), DURECT (DRRX), Unicycive Therapeutics (UNCY), Lexaria Bioscience (LEXX), Cara Therapeutics (CARA), NRx Pharmaceuticals (NRXP), CASI Pharmaceuticals (CASI), and HCW Biologics (HCWB). These companies are all part of the "medical" sector.
Jaguar Health (NASDAQ:JAGX) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.
12.0% of Jaguar Health shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 0.2% of Jaguar Health shares are held by company insiders. Comparatively, 33.4% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Jaguar Health received 1511 more outperform votes than Fortress Biotech when rated by MarketBeat users. Likewise, 89.08% of users gave Jaguar Health an outperform vote while only 64.80% of users gave Fortress Biotech an outperform vote.
Fortress Biotech has a consensus price target of $30.00, suggesting a potential upside of 1,521.62%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Jaguar Health.
Jaguar Health has higher earnings, but lower revenue than Fortress Biotech.
In the previous week, Fortress Biotech had 6 more articles in the media than Jaguar Health. MarketBeat recorded 9 mentions for Fortress Biotech and 3 mentions for Jaguar Health. Fortress Biotech's average media sentiment score of 0.59 beat Jaguar Health's score of 0.22 indicating that Fortress Biotech is being referred to more favorably in the news media.
Fortress Biotech has a net margin of -69.13% compared to Jaguar Health's net margin of -377.95%. Jaguar Health's return on equity of -642.15% beat Fortress Biotech's return on equity.
Jaguar Health has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.
Summary
Fortress Biotech beats Jaguar Health on 10 of the 15 factors compared between the two stocks.
Get Jaguar Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JAGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jaguar Health Competitors List
Related Companies and Tools
